Identification of a Robust Functional Subpathway Signature for Pancreatic Ductal Adenocarcinoma by Comprehensive and Integrated Analyses

Overview

Journal Cell Commun Signal

Publisher Biomed Central

Specialties Biochemistry
Cell Biology

Date 2020 Mar 4

PMID 32122386

Authors

Ping Wang

Chunlong Zhang

Weidong Li

Bo Zhai

Xian Jiang

Shiva Reddy

Hongchi Jiang

Xueying Sun

Affiliations

Soon will be listed here.

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy and its mortality continues to rise globally. Because of its high heterogeneity and complex molecular landscapes, published gene signatures have demonstrated low specificity and robustness. Functional signatures containing a group of genes involved in similar biological functions may display a more robust performance.

Methods: The present study was designed to excavate potential functional signatures for PDAC by analyzing maximal number of datasets extracted from available databases with a recently developed method of FAIME (Functional Analysis of Individual Microarray Expression) in a comprehensive and integrated way.

Results: Eleven PDAC datasets were extracted from GEO, ICGC and TCGA databases. By systemically analyzing these datasets, we identified a robust functional signature of subpathway (path:00982_1), which belongs to the drug metabolism-cytochrome P450 pathway. The signature has displayed a more powerful and robust capacity in predicting prognosis, drug response and chemotherapeutic efficacy for PDAC, particularly for the classical subtype, in comparison with published gene signatures and clinically used TNM staging system. This signature was verified by meta-analyses and validated in available cell line and clinical datasets with chemotherapeutic efficacy.

Conclusion: The present study has identified a novel functional PDAC signature, which has the potential to improve the current systems for predicting the prognosis and monitoring drug response, and to serve a linkage to therapeutic options for combating PDAC. However, the involvement of path:00982_1 subpathway in the metabolism of anti-PDAC chemotherapeutic drugs, particularly its biological interpretation, requires a further investigation. Video Abstract.

References

Li C, Li X, Miao Y, Wang Q, Jiang W, Xu C . SubpathwayMiner: a software package for flexible identification of pathways. Nucleic Acids Res. 2009; 37(19):e131. PMC: 2770656. DOI: 10.1093/nar/gkp667. View

Zhang C, Xu Y, Yang H, Xu Y, Shang D, Wu T . sPAGM: inferring subpathway activity by integrating gene and miRNA expression-robust functional signature identification for melanoma prognoses. Sci Rep. 2017; 7(1):15322. PMC: 5681640. DOI: 10.1038/s41598-017-15631-y. View

Newhook T, Blais E, Lindberg J, Adair S, Xin W, Lee J . A thirteen-gene expression signature predicts survival of patients with pancreatic cancer and identifies new genes of interest. PLoS One. 2014; 9(9):e105631. PMC: 4152146. DOI: 10.1371/journal.pone.0105631. View

Raman P, Maddipati R, Lim K, Tozeren A . Pancreatic cancer survival analysis defines a signature that predicts outcome. PLoS One. 2018; 13(8):e0201751. PMC: 6084949. DOI: 10.1371/journal.pone.0201751. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Makohon-Moore A, Zhang M, Reiter J, Bozic I, Allen B, Kundu D . Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat Genet. 2017; 49(3):358-366. PMC: 5663439. DOI: 10.1038/ng.3764. View

Yang L, Zou S, Shu C, Song Y, Sun Y, Zhang W . CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients. Genomics Proteomics Bioinformatics. 2017; 15(4):255-262. PMC: 5582793. DOI: 10.1016/j.gpb.2016.11.004. View

Yang X, Regan K, Huang Y, Zhang Q, Li J, Seiwert T . Single sample expression-anchored mechanisms predict survival in head and neck cancer. PLoS Comput Biol. 2012; 8(1):e1002350. PMC: 3266878. DOI: 10.1371/journal.pcbi.1002350. View

Kirby M, Ramaker R, Gertz J, Davis N, Johnston B, Oliver P . RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4. Mol Oncol. 2016; 10(8):1169-82. PMC: 5423196. DOI: 10.1016/j.molonc.2016.05.004. View

10.

Mathijssen R, de Jong F, van Schaik R, Lepper E, Friberg L, Rietveld T . Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst. 2004; 96(21):1585-92. DOI: 10.1093/jnci/djh298. View

11.

Ashida R, Okamura Y, Ohshima K, Kakuda Y, Uesaka K, Sugiura T . The down-regulation of the CYP2C19 gene is associated with aggressive tumor potential and the poorer recurrence-free survival of hepatocellular carcinoma. Oncotarget. 2018; 9(31):22058-22068. PMC: 5955155. DOI: 10.18632/oncotarget.25178. View

12.

Collisson E, Sadanandam A, Olson P, Gibb W, Truitt M, Gu S . Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011; 17(4):500-3. PMC: 3755490. DOI: 10.1038/nm.2344. View

13.

. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017; 32(2):185-203.e13. PMC: 5964983. DOI: 10.1016/j.ccell.2017.07.007. View

14.

Shi G, Zhang J, Lu Z, Liu D, Wu Y, Wu P . A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma. Oncotarget. 2018; 8(67):110849-110860. PMC: 5762289. DOI: 10.18632/oncotarget.22861. View

15.

Shi X, Li X, Zhang H, He R, Zhao Y, Zhou M . A Five-microRNA Signature for Survival Prognosis in Pancreatic Adenocarcinoma based on TCGA Data. Sci Rep. 2018; 8(1):7638. PMC: 5955976. DOI: 10.1038/s41598-018-22493-5. View

16.

Moffat G, Epstein A, OReilly E . Pancreatic cancer-A disease in need: Optimizing and integrating supportive care. Cancer. 2019; 125(22):3927-3935. PMC: 6819216. DOI: 10.1002/cncr.32423. View

17.

Li H, Chen Y, Yuan S . Proposal of a modified American Joint Committee on Cancer staging scheme for resectable pancreatic ductal adenocarcinoma with a lymph node ratio-based N classification: A retrospective cohort study. Medicine (Baltimore). 2018; 97(34):e12094. PMC: 6112900. DOI: 10.1097/MD.0000000000012094. View

18.

Ma S, Kosorok M, Huang J, Dai Y . Incorporating higher-order representative features improves prediction in network-based cancer prognosis analysis. BMC Med Genomics. 2011; 4:5. PMC: 3037289. DOI: 10.1186/1755-8794-4-5. View

19.

Allen P, Kuk D, Fernandez-Del Castillo C, Basturk O, Wolfgang C, Cameron J . Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma. Ann Surg. 2016; 265(1):185-191. PMC: 5611666. DOI: 10.1097/SLA.0000000000001763. View

20.

Wang Y, Li Y, Lu J, Qi H, Cheng I, Zhang H . Involvement of CYP4F2 in the Metabolism of a Novel Monophosphate Ester Prodrug of Gemcitabine and Its Interaction Potential In Vitro. Molecules. 2018; 23(5). PMC: 6100113. DOI: 10.3390/molecules23051195. View